Stentrode

Stentrode is a brain-computer interface built into a self-expanding stent. Instead of opening the skull, a neurointerventional radiologist threads the device through the jugular vein into the superior sagittal sinus, the large vein running along the midline of the brain, where it expands against the vessel wall directly above motor cortex. Electrodes on the stent record cortical activity through the vein wall, and a lead runs under the skin of the neck to a telemetry unit implanted in the chest, which transmits wirelessly to an external computer.

The design gives up signal quality in exchange for surgical accessibility. Its sixteen electrodes record population-level activity rather than individual neurons, so the Stentrode captures far less information than a penetrating Utah array. It also needs no craniotomy, relies on catheter techniques that thousands of clinicians already practise, and places no foreign material in the brain parenchyma.

§How it works

The stent is a nitinol mesh of the type used to treat venous stenosis, with electrode contacts mounted on its struts. It is delivered collapsed inside a catheter, self-expands on release, and presses the electrodes against the endothelium. Over the following weeks the vessel wall incorporates the stent. This is the same endothelialization that makes vascular stents stable, and here it fixes the electrodes in position without sutures or bone anchors.

Signals reach the electrodes through the vein wall, which acts as a spatial filter. What the device records resembles the output of the surface arrays used in Electrocorticography interfaces, but with fewer, larger and more distant contacts: local field potentials and band power rather than action potentials. Participants generate control signals by attempting movements, typically of a foot or ankle, since the leg representation of motor cortex sits along the midline nearest the sagittal sinus. A decoder maps the resulting change in band power to a discrete output that the company calls a digital motor output, which is essentially a click.

One reliable click is not enough to run a computer, so the system is used with eye tracking or switch-scanning software: gaze selects the target and the neural signal confirms it. The division of labour is deliberate. The Neural decoding problem is much easier when the decoder only has to distinguish attempted movement from rest.

§Development history

The concept came from Thomas Oxley and Nicholas Opie's group at the University of Melbourne. They reasoned that the cerebral venous system already reaches within millimetres of cortex, and that catheter delivery would avoid the complication profile of open neurosurgery. A 2016 report in sheep showed that an endovascular array could record cortical activity chronically, with signal quality that remained usable as the stent was incorporated into the vessel wall.¹ Synchron was founded to commercialize the device.

The first-in-human study, SWITCH, implanted the device in four participants with severe paralysis, mostly from amyotrophic lateral sclerosis, at the Royal Melbourne Hospital beginning in 2019. The published results reported no device-related serious adverse events and no vessel occlusion, and participants were able to use the system with eye tracking for texting, email and online banking.²³ A United States early feasibility study, COMMAND, began in 2022 with the first implant at Mount Sinai in New York, and the company has reported that its primary safety endpoint was met.

1. 2016
   Chronic recording in sheep
   An endovascular stent-electrode array records cortical activity for months, published in Nature Biotechnology.
2. 2019-2021
   SWITCH first-in-human study
   Four participants with severe paralysis receive implants in Australia; the trial reports no device-related serious adverse events.
3. 2022
   First US implant
   The COMMAND early feasibility study begins at Mount Sinai under an FDA investigational device exemption.
4. 2023-2025
   Integration with consumer platforms
   Synchron demonstrates control of commercial voice assistants and announces work with major computing platforms on native input support for neural devices.

§Clinical results and limits

Participants have demonstrated something real but narrow: reliable discrete selection sufficient for communication and device control, sustained over months to years, in people who otherwise depend on eye-gaze systems that fail when eye movement deteriorates. For a population with few options, that is a meaningful clinical benefit.

Continuous high-dimensional control has not been demonstrated. No endovascular device has produced anything resembling the robotic-arm work or the fluent Speech neuroprosthesis results obtained with penetrating arrays,⁴ and there is a physical reason to expect the gap to persist. Speech motor cortex lies on the lateral surface of the brain, far from the sagittal sinus. The venous anatomy determines which cortex is reachable, and it does not reach everywhere. Driving a wheelchair or a powered Powered exoskeletons would likewise require continuous multi-axis control that a click cannot supply.

Bandwidth versus access

Synchron argues that a device a vascular surgeon can implant in an ordinary catheter lab scales to a patient population that craniotomy never will, and that reliable simple control covers most of the clinical need. Critics respond that sixteen field-potential channels cap the device below the applications that justify an implant at all, and that the right comparison is with non-invasive eye trackers rather than with penetrating arrays.

Other limitations follow from the vascular setting. The device is difficult to remove once the vein wall has grown over it. Participants need antiplatelet therapy, at least initially, and venous thrombosis or stenosis remains the principal safety concern even though the published studies did not observe it. Long-term stability data extend to a few years in a small number of participants, which is not enough to characterize rare complications.

§Strategy and context

Synchron has positioned the Stentrode against both invasive and non-invasive alternatives. Compared with Neuralink and other penetrating systems, it accepts a much lower ceiling in exchange for a procedure that generalists can perform. Compared with Non-invasive neuromodulation and scalp-electrode devices, it offers a stable signal that is always available, needs no setup, and is not exposed to hair and sweat artefacts.

The company has also pursued integration with mainstream computing platforms, so that a neural device appears to an operating system as an input source alongside touch and voice. If that standardization takes hold, its effect would extend beyond any one device, because the persistent complaint from users of assistive Neuroprosthetics is that the hardware works and the software ecosystem does not.

§Outlook

The obvious next step is a pivotal trial in a defined indication that could support market authorization, with loss of communication in ALS the clearest candidate. No implanted BCI has cleared that bar anywhere. The Stentrode's low channel count may help here, because a simpler device with a simpler claim is easier to evaluate. The existing regulatory precedents are for stimulating devices such as the Cochlear implant and Deep brain stimulation systems, where the therapeutic claim is a change in symptoms rather than a measured rate of communication.

The unresolved technical question is whether channel count can grow. Multiple stents, longer arrays extending further along the sinus, and improved electrode materials have all been proposed. It has not been established whether any of these lifts an endovascular interface out of the switch-like regime, or whether the vein wall imposes a hard ceiling on what can be resolved. As with every implanted neural device, the governance questions arrive before the clinical ones are settled: data ownership, Mental privacy, obligations to support the device, and the Neurorights frameworks now emerging in several jurisdictions.

§See also

• Synchron
• Brain–computer interface
• Utah array
• Electrocorticography interfaces
• Neuralink
• Neural decoding
• Neuroprosthetics
• Speech neuroprosthesis

§References